TFPI or uPA-PAI-1 complex affect cell function through expression variation of type II very low density lipoprotein receptor

FEBS Letters
Yong DiShen Qu

Abstract

Very low density lipoprotein receptors (VLDLR) including type I and type II are known to affect cell functions by binding to its extracellular ligands. However, the effect of these ligands on VLDLR expression remains elusive. Tissue factor pathway inhibitor (TFPI) and urokinase plasminogen activator and plasminogen activator inhibitor 1 (uPA-PAI-1) complex, two ligands of VLDLR, were used to examine their effects on VLDLR expression. TFPI treatment decreased type II VLDLR expression, inhibited cell proliferation and migration, and degradated beta-catenin in SGC7901 cells. However, uPA-PAI-1 complex, increased type II VLDLR expression with promoted cell proliferation and migration and stabilization of beta-catenin. These results indicated that extracellular ligands can change the expression of type II VLDLR to affect cell proliferation and migration.

References

Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·S TakahashiT Yamamoto
Jan 11, 2000·Archives of Pathology & Laboratory Medicine·Y NakamuraE Kumamaru
Jun 21, 2002·Trends in Cell Biology·Anders Nykjaer, Thomas E Willnow
Dec 10, 2002·Biochemical and Biophysical Research Communications·Hiroko Shirotani-IkejimaToshiyuki Miyata
Jul 8, 2003·The Journal of Pathology·Ivan Stamenkovic
Jul 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hippokratis KiarisAnastasios Kalofoutis
Dec 8, 2004·Current Cancer Drug Targets·Hue H LuuTong-Chuan He
Oct 30, 2007·Translational Research : the Journal of Laboratory and Clinical Medicine·Xiaoran QinLihong Ye

❮ Previous
Next ❯

Citations

Dec 3, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M RíosR Señarís
Apr 12, 2017·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Lei HeZhi-Guo Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.